Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial / GETNE 1601)

被引：0
|
作者：
Hernando-Cubero, J. [1 ]
Manzano, J. L. [2 ]
Benavent, M. [3 ]
Lopez, C. [4 ]
Teule, R. [5 ]
Garcia-Carbonero, R. [6 ]
Carmona-Bayonas, A. [7 ]
Crespo, G. [8 ]
Cubillo, A. [9 ]
Jimenez-Fonseca, P. [10 ]
LaCasta, A. [11 ]
Capdevila, J. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Inst Catala Oncol Badalona, Barcelona, Spain
[3] Hosp Virgen del Rocio, Seville, Spain
[4] Hosp Univ Marques de Valdecilla, Santander, Spain
[5] Inst Catala Oncol Hosp, Barcelona, Spain
[6] Hosp Univ 12 Octubre, Madrid, Spain
[7] HJM Morales Meseguer, Murcia, Spain
[8] Hosp Univ Burgos, Burgos, Spain
[9] Hosp Univ Madrid Sanchinarro, Madrid, Spain
[10] Hosp Univ Cent Asturias, Oviedo, Spain
[11] Hosp Univ Donostia, San Sebastian, Spain
来源：
NEUROENDOCRINOLOGY | 2018年 / 106卷
关键词：
durvalumab; tremelimumab; neuroendocrine; immunotherapy;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
J10
引用
收藏
页码：228 / 228
页数：1
相关论文
共 50 条
  • [41] Durvalumab (D) plus /- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial
    Thibault, C.
    Bennamoun, M.
    Flechon, A.
    Gravis, G.
    Pouessel, D.
    Combe, P-F.
    Borchiellini, D.
    Loriot, Y.
    Laguerre, B.
    Barthelemy, P.
    Goupil, M. Gross
    Helissey, C.
    Huillard, O.
    Cancel, M.
    Campedel, L.
    Audenet, F.
    Belhouari, H.
    Kotti, S.
    Tran, Y.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1202 - S1202
  • [42] Cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy: Safety and preliminary activity of the open-label, single-arm, phase II ARCADIA trial
    Marandino, L.
    Raggi, D.
    Giannatempo, P.
    Calareso, G.
    Alessi, A.
    Colecchia, M.
    Madison, R.
    Ross, J. S.
    Necchi, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S595 - S595
  • [43] Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial
    Zhang, Yaxiong
    Huang, Yan
    Yang, Yunpeng
    Zhao, Yuanyuan
    Zhou, Ting
    Chen, Gang
    Zhao, Shen
    Zhou, Huaqiang
    Ma, Yuxiang
    Hong, Shaodong
    Zhao, Hongyun
    Zhang, Li
    Fang, Wenfeng
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [44] Vinorelbine plus best supportive care (BSC) vs BSC in the treatment of advanced non small cell lung cancer (NSCLC) elderly patients (pts). Results of a phase III randomized trial
    Clerici, M
    Frontini, L
    Ianniello, GP
    Maiorino, L
    Piantedosi, FV
    Cigolari, S
    Manzione, L
    Failla, G
    Zuccarino, L
    Pedicini, T
    Vinante, O
    Castiglione, F
    Bearz, A
    Tonato, M
    Rossi, A
    Monfardini, S
    Gallo, C
    Perrone, F
    Gridelli, C
    ANNALS OF ONCOLOGY, 1998, 9 : 62 - 62
  • [45] Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion plus non-small cell lung cancer (NSCLC).
    Gainor, Justin F.
    Curigliano, Giuseppe
    Kim, Dong-Wan
    Lee, Dae Ho
    Besse, Benjamin
    Baik, Christina S.
    Doebele, Robert C.
    Cassier, Philippe Alexandre
    Lopes, Gilberto
    Tan, Daniel Shao-Weng
    Garralda, Elena
    Paz-Ares, Luis G.
    Cho, Byoung Chul
    Gadgeel, Shirish M.
    Thomas, Michael
    Liu, Stephen, V
    Clifford, Corinne
    Zhang, Hui
    Turner, Christopher D.
    Subbiah, Vivek
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): Updated results from the phase II TALENT trial (GETNE 1509).
    Capdevila, Jaume
    Fazio, Nicola
    Lopez-Lopez, Carlos
    Teule, Alexandre
    Valle, Juan W.
    Tafuto, Salvatore
    Custodio, Ana B.
    Reed, Nicholas
    Raderer, Markus
    Grande, Enrique
    Garcia-Carbonero, Rocio
    Jimenez-Fonseca, Paula
    Alonso, Vicente
    Antonuzzo, Lorenzo
    Spallanzani, Andrea
    Berruti, Alfredo
    Sevilla, Isabel
    La Casta Munoa, Adelaida
    Hernando, Jorge
    Ibrahim, Toni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [47] Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial.
    West, H
    Belt, RJ
    Wakelee, HA
    Bloss, LP
    Taylor, L
    Monberg, MJ
    Ye, Z
    Obasaju, CK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 649S - 649S
  • [48] Vinorelbine (VNR) plus best supportive care (BSC) vs BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (Pts). Results of a phase III randomized trial
    Gridelli, C
    Ianniello, GP
    Maiorino, L
    Brancaccio, L
    Cigolari, S
    Bilancia, D
    Aiello, R
    Zuccarino, L
    Pedicini, T
    Zonato, S
    Pappagallo, GL
    Monfardini, S
    Rossi, A
    Gallo, C
    Perrone, F
    BRITISH JOURNAL OF CANCER, 1998, 78 : 3 - 3
  • [49] Vinorelbine(VNR) plus best supportive care (BSC) vs BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (pts). Results of a phase III randomized trial
    Gridelli, C
    Ianniello, GP
    Maiorino, L
    Piantedosi, V
    Cigolari, S
    Manzione, L
    Failla, G
    Zuccarino, L
    Pedicini, T
    Vinante, O
    Castiglione, F
    Clerici, M
    Bearz, A
    Darwish, S
    Rossi, A
    Monfardini, S
    Gallo, C
    Perrone, F
    Frontini, L
    ANNALS OF ONCOLOGY, 1998, 9 : 85 - 85
  • [50] Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab plus Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial
    Heymach, John, V
    Mitsudomi, Tetsuya
    Harpole, David
    Aperghis, Mike
    Jones, Stephanie
    Mann, Helen
    Fouad, Tamer M.
    Reck, Martin
    CLINICAL LUNG CANCER, 2022, 23 (03) : E247 - E251
12345